Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population
Article first published online: 22 SEP 2006
Copyright © 2006 John Wiley & Sons, Ltd.
International Journal of Geriatric Psychiatry
Volume 22, Issue 4, pages 294–304, April 2007
How to Cite
Rami, L., Molinuevo, J. L., Sanchez-Valle, R., Bosch, B. and Villar, A. (2007), Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Int. J. Geriat. Psychiatry, 22: 294–304. doi: 10.1002/gps.1672
- Issue published online: 21 MAR 2007
- Article first published online: 22 SEP 2006
- Manuscript Accepted: 11 JUL 2006
- Manuscript Received: 10 APR 2006
- mild cognitive impairment;
- Alzheimer's disease;
- cognition disorders;
- neuropsychological tests;
To design and validate a new screening test for amnestic Mild Cognitive Impairment (A-MCI) and early stage Alzheimer's disease (AD).
We develop a verbal episodic and semantic memory test: the Memory Alteration Test (M@T). Discriminative validity was assessed in a population sample of 400 aged individuals from primary care population centres in Barcelona, Spain, 50 patients with A-MCI according to Petersen et al. criteria, and 66 with early AD (Global Deterioration Scale—4 stage) according to the NINCDS-ADRDA criteria.
The M@T is quick, 5-min, and easy to administer and to score. M@T mean scores were significantly different between all groups: 41.4 (SD = 4.9) in the primary care population, 31.5 (SD = 3.9) in the A-MCI group and 21.8 (SD = 4.9) in early AD. A cut-off score of 37 points had a sensitivity of 96% and a specificity of 79% for A-MCI diagnosis (AUC = 0.932). A cut-off score of 28 points had a sensitivity of 92% and a specificity of 98% for early AD diagnosis (AUC = 0.99) and a sensitivity of 87 % and specificity of 82% to differentiate between A-MCI and AD patients.
The M@T provides efficient and valid screening for A-MCI and early stage AD, and discriminates between A-MCI and early AD patients. Copyright © 2006 John Wiley & Sons, Ltd.